Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs

Truist Securities initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $10.00

Needham initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $12.00

Maxim Group initiated coverage of Clarus Therapeutics with a rating of Buy and set a new price target of $13.00

15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba

NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate). Patent application No. 16/656,169 e

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at ENDO 2022, the Endocrine Society's annual meeting, taking place at the Georgia World Congress Center in Atlanta June 11-14, 2022. Details on the abstra

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA's Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Claru

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the first quarter of 2022. "We delivered a strong first quarter, as the total number of prescriptions written for JATENZO continued to increase," said Dr. R

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR-121 for the treatment of PDM anticipated in the second half of 2022 NORTHBROOK, Ill., May 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for

Gainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares surged 103.9% to settle at $5.30 on Tuesday. Shares are in low-float territory; the issue has about 15 million shares in its float. NewAge, Inc. (NASDAQ:NBEV) shares jumped 74.2% to close at $0.3632 on Tuesday. IN8bio, Inc. (NASDAQ:INAB) surged 39.4% to settle at $2.76 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. TMC the metals company Inc. (NASDAQ:TMC) jumped 33.3% to close at $1.12. The company recently posted a quarterly loss of $0.05 per share. TDH Holdings, Inc. (NASDAQ:P

Gainers NewAge, Inc. (NASDAQ:NBEV) rose 54.4% to $0.3220. IN8bio, Inc. (NASDAQ:INAB) jumped 46% to $2.89 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. Mobile Global Esports Inc. (NASDAQ:MGAM) shares jumped 45% to $3.7705. Shares are in low-float territory; the issue has about 15 million shares in its float. Forge Global Holdings, Inc. (NYSE:FRGE) gained 26.7% to $4.37. Virax Biolabs Group Limited (NASDAQ:VRAX) gained 20% to $3.94. American Outdoor Brands, Inc. (NASDAQ:AOUT) surged 18% to $9.17 after B. Riley upgraded the stock from

  On Tuesday, 250 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Toyota Motor (NYSE:TM) was the biggest company on a market cap basis to set a new 52-week low. SciSparc (NASDAQ:SPRC) was the smallest firm by market cap to set a new 52-week low. Rubicon Technology (NASDAQ:RBCN)'s stock traded down the lowest, falling 74.66% to reach a new 52-week low. Grupo Aval Acciones (NYSE:AVAL)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low. On Tuesday, the following stocks set new 52-week lows: Toyota Motor (NYSE:TM) stock drifted down 0.45% on Tuesday morning to hit a new 52-week low of $150.59. Comcast (NASDA

Gainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares rose 28.1% to $3.33 in pre-market trading after gaining over 5% on Monday. The company recently reported an exclusive compression technology partnership for upcoming Indian esports social-gaming platform. American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) shares rose 18.3% to $0.4435 in pre-market trading after jumping 156% on Monday. American Virtual Cloud Technologies recently announced changes to its board of directors and management team, along with the launch of a review to explore the sale of the entire business or selected assets. Sharps Technology, Inc. (NASDAQ:STSS) rose 13.7% to $1.58 in pre-market trading. NewAge,

Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) shares traded lower by 32.24% to $0.14 during Monday's trading session after the company announced it has received a non-compliance letter from Nasdaq. The shares will be suspended on August 31st and will begin trading on the OTC Pink Market. What Else? Clarus Therapeutics says, as previously disclosed on February 18th, 2022, the company received two written notifications from the Listing Qualifications Department of Nasdaq. Clarus Therapeutics says the first notification indicated that as of February 18th, Clarus did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in N

Gainers Advanced Human Imaging Limited (NASDAQ:AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed a Master Services Agreement with Estonia-based Activate Health OÜ. American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 41.4% to $0.2068. American Virtual Cloud Technologies shares gained around 8% on Friday after the company announced changes to its board of directors and management team, along with the launch of a review to explore the sale of the entire business or selected assets. Minerva Neurosciences, Inc. (NASDAQ:NERV) jumped 25% to $12.96. Point72 Asset Management recently reported an 8.8% passive stake in the company. Pinduoduo Inc. (NASDAQ

  On Monday, 273 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: Toyota Motor (NYSE:TM) was the largest firm by market cap to set a new 52-week low. The company with the smallest market cap to set a new 52-week low was First Wave BioPharma (NASDAQ:FWBI). Athersys (NASDAQ:ATHX) saw the most pronounced move, as shares traded down 2215.46% to hit its new 52-week low. Innodata (NASDAQ:INOD)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low. The following stocks set new 52-week lows on Monday: Abbott Laboratories (NYSE:ABT) stock hit a yearly low of $101.21. The stock was down 0.56% for the day. Comcast (NAS

Gainers NewAge, Inc. (NASDAQ:NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q. Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares rose 18.1% to $3.01 in pre-market trading after declining around 12% on Friday. American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 16.2% to $0.1700 in pre-market trading. American Virtual Cloud Technologies shares gained around 8% on Friday after the company announced changes to its board of directors and management team, along with the launch of a review to explore the sale of the entire business or selected assets. Bit Origin Limited (NASDAQ:BTOG) rose 15.1% to $0.43